Frequency of allogeneic hematopoietic cell transplantation among patients with high- Or intermediate-risk acute myeloid leukemia in first complete remission

Journal of Clinical Oncology

Volumn 31, Issue 31, 2013, Pages 3883-3888

  Mawad, Raya ^a,b   Gooley, Ted A ^a   Sandhu, Vicky ^a   Lionberger, Jack ^c   Scott, Bart ^a,b   Sandmaier, Brenda M ^a,b   O'Donnell, Paul ^a,b   Becker, Pamela S ^a,b   Petersdorf, Stephen ^a,b   Dorcy, Kathleen Shannon ^a   Hendrie, Paul ^a,b   Sorror, Mohamed L ^a,b   Walter, Roland B ^a,b   Deeg, H Joachim ^a,b   Appelbaum, Frederick R ^a,b   Estey, Elihu H ^a,b   Pagel, John M ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c SAINT LOUIS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN; IDARUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLOOD CELL COUNT; COMORBIDITY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; REMISSION; YOUNG ADULT; ADOLESCENT; ALLOTRANSPLANTATION; LEUKEMIA, MYELOID, ACUTE; MORTALITY; NEOPLASM RECURRENCE, LOCAL; RISK FACTOR; STATISTICS AND NUMERICAL DATA; STATISTICS; TUMOR RECURRENCE;

ADOLESCENT; ADULT; AGED; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; REMISSION INDUCTION; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84891648849     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.50.2567     Document Type: Article

References (23)

1. Wheatley K, Gray R: Commentary: Mendelian randomization - An update on its use to evaluate allogeneic stem cell transplantation in leukaemia. Int J Epidemiol 33:15-17, 2004 (Pubitemid 38500148)
2. Koreth J, Schlenk R, Kopecky KJ, et al: Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: Systematic review and meta-analysis of prospective clinical trials. JAMA 301:2349-2361, 2009
3. Cornelissen JJ, van Putten WL, Verdonck LF, et al: Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: Benefits for whom? Blood 109:3658-3666, 2007 (Pubitemid 46641712)
4. Kurosawa S, Yamaguchi T, Miyawaki S, et al: A Markov decision analysis of allogeneic hematopoietic cell transplantation versus chemotherapy in patients with acute myeloid leukemia in first remission. Blood 117:2113-2120, 2011
5. Yanada M, Matsuo K, Emi N, et al: Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: A metaanalysis. Cancer 103:1652-1658, 2005 (Pubitemid 40490026)
6. Schlenk RF, Döhner K, Krauter J, et al: Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 358:1909-1918, 2008 (Pubitemid 351620111)
7. Appelbaum FR, Pearce SF: Hematopoietic cell transplantation in first complete remission versus early relapse. Best Pract Res Clin Haematol 19:333-339, 2006
8. Appelbaum FR: Allogeneic hematopoietic cell transplantation for acute myeloid leukemia when a matched related donor is not available. Hematology Am Soc Hematol Educ Program 412-417, 2008
9. Appelbaum FR: What is the impact of hematopoietic cell transplantation (HCT) for older adults with acute myeloid leukemia (AML)? Best Pract Res Clin Haematol 21:667-675, 2008
10. Moore J, Nivison-Smith I, Goh K, et al: Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant 13:601-607, 2007 (Pubitemid 46585933)
11. Schetelig J, Bornhäuser M, Schmid C, et al: Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: A report from the cooperative German Transplant Study Group. J Clin Oncol 26:5183-5191, 2008
12. Walter RB, Pagel JM, Gooley TA, et al: Comparison of matched unrelated and matched related donor myeloablative hematopoietic cell transplantation for adults with acute myeloid leukemia in first remission. Leukemia 24:1276-1282, 2010
13. Eapen M, Rocha V, Sanz G, et al: Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: A retrospective analysis. Lancet Oncol 11:653-660, 2010
14. Brunstein CG, Gutman JA, Weisdorf DJ, et al: Allogeneic hematopoietic cell transplantation for hematologic malignancy: Relative risks and benefits of double umbilical cord blood. Blood 116:4693-4699, 2010
15. Ballen KK, Koreth J, Chen YB, et al: Selection of optimal alternative graft source: Mismatched unrelated donor, umbilical cord blood, or haploidentical transplant. Blood 119:1972-1980, 2012
16. Aversa F: Haploidentical haematopoietic stem cell transplantation for acute leukaemia in adults: Experience in Europe and the United States. Bone Marrow Transplant 41:473-481, 2008
17. Estey E, de Lima M, Tibes R, et al: Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood 109:1395-1400, 2007 (Pubitemid 46239569)
18. Cheson BD, Bennett JM, Kopecky KJ, et al: Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21:4642-4649, 2003 (Pubitemid 46594039)
19. Döhner H, Estey EH, Amadori S, et al: Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115:453-474, 2010
20. Vardiman JW, Thiele J, Arber DA, et al: The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 114:937-951, 2009
21. Sorror ML, Giralt S, Sandmaier BM, et al: Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: Combined FHCRC and MDACC experiences. Blood 110: 4606-4613, 2007 (Pubitemid 351377830)
22. Sorror ML, Maris MB, Storb R, et al: Hematopoietic cell transplantation (HCT)-specific comorbidity index: A new tool for risk assessment before allogeneic HCT. Blood 106:2912-2919, 2005 (Pubitemid 41510773)
23. Schlenk RF, Döhner K, Mack S, et al: Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A. J Clin Oncol 28:4642-4648, 2010